Two Shares Face To Face: Sally Beauty Holdings, Inc. (NYSE:SBH), Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Sally Beauty Holdings, Inc. (NYSE:SBH)

Sally Beauty Holdings, Inc. (NYSE:SBH) closed at $11.85 on the last trading session with an decrease of -0.67%, whereas, it previously closed at $11.93. The company has a market capitalization of $1.42 Billion. The company traded shares of 1.92 Million on the trading day while its three month average volume stands at 1.78 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Sally Beauty Holdings, Inc. (NYSE:SBH) produced diluted EPS of 1.97. The EPS estimate for next year as estimated by analysts is at 2.17 while EPS for next quarter is estimated at 0.58. Earnings per Share growth for this year is reported at 20.4, while the analysts estimated the EPS growth for next year at 2.17% and Earnings growth for next 5 years stands at 3.45% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at 4.8%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Sally Beauty Holdings, Inc. (NYSE:SBH) is at 6.02 while the forward p/e is at 5.46. The P/S or Price to Sales ratio of Sally Beauty Holdings, Inc. (NYSE:SBH) stands at 0.37 and Price to Book or P/B for the most recent quarter stands at 0. The Price to Free Cash Flow ratio or P/FCF is reported at 6.8. The quick ratio and the current ratio of Sally Beauty Holdings, Inc. (NYSE:SBH) are reported at 0.5 and 2.8 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Sally Beauty Holdings, Inc. (NYSE:SBH) stands at 11.6, -102.6 and 21.9 respectively

The trailing twelve month Revenue of Sally Beauty Holdings, Inc. (NYSE:SBH) is reported at 3.9 Billion with income of 238.1 Million. The outstanding shares of Sally Beauty Holdings, Inc. (NYSE:SBH) are 120.08 Million. The institutional Ownership of the shares of 0 stands at 0.80%, this figure is decreased -0.99 in the last six months. The insider ownership for the shares of Sally Beauty Holdings, Inc. (NYSE:SBH) is ticked at 0.5%, the figure is rose 6.04% in the last six months.

Some other important financial aspects to be discussed here for Sally Beauty Holdings, Inc. (NYSE:SBH) is the Mean Target Price estimated by the analysts which stands at 15.44. The 52 week high of Sally Beauty Holdings, Inc. (NYSE:SBH) is placed at 23.61 and 52 week low is standing at 11.84.

Performance wise the shares of Sally Beauty Holdings, Inc. (NYSE:SBH) fell down -3.19% for the week, it also fell -18.89% for the monthly performance, while for the quarter it went up -36.53%. The shares decrease -32.56% for the half year and plummeted for the Year-To-Date performance. The shares of Sally Beauty Holdings, Inc. (NYSE:SBH) shrinked -26.76% for the yearly performance.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) closed at $74.11 on the last trading session with an increase of 1.19%, whereas, it previously closed at $73.24. The company has a market capitalization of $7.73 Billion. The company traded shares of 733915 on the trading day while its three month average volume stands at 963.08 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) produced diluted EPS of -7.88. The EPS estimate for next year as estimated by analysts is at -7.27 while EPS for next quarter is estimated at -1.85. Earnings per Share growth for this year is reported at -39.8, while the analysts estimated the EPS growth for next year at -7.27% and Earnings growth for next 5 years stands at 46.09% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at -39.2%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is at 0 while the forward p/e is at 0. The P/S or Price to Sales ratio of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stands at 89.62 and Price to Book or P/B for the most recent quarter stands at 5.05. The Price to Free Cash Flow ratio or P/FCF is reported at 0. The quick ratio and the current ratio of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) are reported at 9.1 and 9.3 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stands at -45.5, -53.9 and -59.7 respectively

The trailing twelve month Revenue of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is reported at 86.3 Million with income of -802200000. The outstanding shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) are 104.36 Million. The institutional Ownership of the shares of 92.3 stands at 0.80%, this figure is increased 4.83 in the last six months. The insider ownership for the shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is ticked at 0.4%, the figure is plummeted -13.38% in the last six months.

Some other important financial aspects to be discussed here for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is the Mean Target Price estimated by the analysts which stands at 121.61. The 52 week high of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is placed at 124.21 and 52 week low is standing at 60.27.

Performance wise the shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rose up 1.56% for the week, it also rise 4.79% for the monthly performance, while for the quarter it went up -16.65%. The shares decrease -13.16% for the half year and flew up for the Year-To-Date performance. The shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shrinked -27.89% for the yearly performance.